Price Alert

Collegium Pharmaceutical ... (COLL)

NASDAQ: COLL · Real-Time Price · USD

37.71

0.55 (1.48%)

At close: Aug 15, 2025, 3:59 PM

37.74

0.08%

After-hours: Aug 15, 2025, 04:34 PM EDT

1.48% (1D)

Bid	35.35
Market Cap	1.19B
Revenue (ttm)	664.28M
Net Income (ttm)	43.89M
EPS (ttm)	1.06
PE Ratio (ttm)	35.58
Forward PE	5.15
Analyst	Buy

Ask	38.18
Volume	170,228
Avg. Volume (20D)	317,375
Open	37.38
Previous Close	37.16
Day's Range	37.12 - 37.85
52-Week Range	23.23 - 42.29
Beta	0.68

About COLL

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol COLL

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for COLL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Collegium Pharmaceutical has released their quartely earnings on Aug 7, 2025:

Revenue of $188M exceeds estimates by $7.1M, with 29.41% YoY growth.

EPS of 1.68 misses estimates by -0.22, with 3.70% YoY growth.

Next Earnings Release

Collegium Pharmaceutical Inc. is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 months ago

+2.22%

Collegium Pharmaceuticals shares are trading highe... Unlock content with Pro Subscription

5 months ago

+0.25%

Collegium Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

News

1 week ago · seekingalpha.com

Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Colleen Tupper - Executive VP & CFO Ian Karp - Corporate Participant Scott...

1 week ago · fool.com

Collegium (COLL) Q2 Revenue Jumps 29%

1 week ago · zacks.com

Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare w...

1 week ago · zacks.com

Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.68 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.62 per share a year ago.

3 weeks ago · zacks.com

Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High?

The consensus price target hints at a 33.9% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...

3 weeks ago · zacks.com

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

1 month ago · marketbeat.com

5 Hot Stocks With Summer Buybacks You Can Cash In On

Stock buybacks remain one of the most effective tools for boosting share prices, especially when backed by solid fundamentals. When a company is healthy, repurchasing shares reduces the float, enhance...

1 month ago · seekingalpha.com

Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug

Collegium is shifting focus from opioids to ADHD with Jornay PM, which is showing strong prescription growth and could become a blockbuster product. The company is undervalued relative to peers, with ...